PAR 0.00% 23.0¢ paradigm biopharmaceuticals limited..

Ann: CHIKV study data published in Peer-Reviewed Journal, page-5

  1. 2,893 Posts.
    lightbulb Created with Sketch. 739
    Further confirmation of ability of PPS to manage inflammation and assist with repair.
    "In contrast, CHIKV infected PPS-treated mice displayed a visible reduction in the overall number of infiltrates in these structures of the hind limbs indicating that PPS protected muscle fibres from damage. Furthermore, PPS treatment appeared to accelerate the inflammatory repair processes with evidence of an increase in the number of regenerating myocytes."

    and safety:
    "Control uninfected animals did not show changes in cartilage proteoglycans. While bone integrity was assessed histologically and scored based
    on osteoclast/osteoblast activity, bone necrosis and vascular changes there were no significant changes observed with PPS treatment.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.0¢
Change
0.000(0.00%)
Mkt cap ! $80.45M
Open High Low Value Volume
23.5¢ 24.0¢ 23.0¢ $122.3K 521.4K

Buyers (Bids)

No. Vol. Price($)
9 330565 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 50000 1
View Market Depth
Last trade - 16.10pm 19/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.